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Abstract
The reported incidence of local recurrence of peripheral atypical lipomatous tumours is highly variable and is
likely to reflect the different inclusion criteria of cases, and the design of previous studies. We aimed to
study the incidence of local recurrence of 90 cases of atypical lipomatous tumours and an additional 18 cases
of de novo dedifferentiated liposarcoma. All tumours were diagnosed on the basis of MDM2 amplification: all
patients had their first treatment in the same specialist sarcoma unit and were followed for a minimum of
60 months. The tumours were diagnosed between 1997 and 2009 and followed until the end of 2014.
Seventy cases (78%) of atypical lipomatous tumours were located in the thigh (mean size 195mm on presen-
tation). Eight atypical lipomatous tumours (8.9%) recurred locally, of which 50% recurred after 60 months.
The only two tumours with intralesional excisions recurred. Seven of the eight recurrent tumours were
detected by the patient by self-examination. One case recurred a second time as a dedifferentiated liposar-
coma. Seventeen per cent of the de novo dedifferentiated liposarcomas recurred within 60 months of presen-
tation. Extending the study period revealed that atypical lipomatous tumour could recur up to 40 years after
the first surgery. Furthermore, of 26 tumours that recurred in the extended study, 27% recurred more than
once, and three of the seven that recurred more than once transformed into a dedifferentiated liposarcoma.
We recommend that, following post-operative wound care, patients with atypical lipomatous tumour are
referred back to their general practitioner for follow up, but that in the event of a suspected recurrence they
have rapid access back to the specialist unit using a ‘supported discharge’ scheme. In the event of an intrale-
sional excision and if a lesion recurs, patients are followed in a specialist unit at regular intervals: whether
MRI scanning is a valuable means of monitoring such patients is unclear and requires an evidence base
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Introduction
Benign and malignant lipomatous neoplasms account
for approximately 50% of all soft tissue tumours.
Liposarcoma, including the atypical lipomatous
tumours (ALT) and dedifferentiated (DDLS), myxoid
and pleomorphic variants, is the single most common
soft tissue sarcoma of adulthood, accounting for
approximately 20% of all soft tissue sarcomas. ALT
account for approximately 45% of all liposarcomas:
these well-differentiated low grade lipomatous
tumours are slow-growing and locally aggressive,
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and only show potential for metastasis following
dedifferentiation. The clinical outcome of centrally
sited (retroperitoneal and chest cavity) tumours is
well recognised as being poor, with recurrence and
mortality being as high as 80% over a period of 10–
20 years [1]. In contrast, the documented incidence
of local recurrence for peripheral ALT appears to be
considerably lower but highly variable [2–8] ranging
from 8% [2,9] to 27% [1,5] to 52% [4]. The variation
in these figures requires explanation.
In view of the widely variable reported incidence of
local recurrence of peripheral ALT, which is likely to
reflect the different criteria for inclusion into the stud-
ies, our primary aim was to provide an evidence base
on which to plan clinical management and follow-up
of patients presenting with a peripheral ALT. This was
achieved by generating robust information on the
clinical outcome of 90 patients who presented with
peripherally-sited ALT: the tumours were diagnosed
using the strict criterion of the presence of tumour
MDM2 amplification, and all patients had their first sur-
gical treatment in our specialist unit and were followed
for a minimum of 60 months. The secondary aim of the
project was to identify the percentage of ALT that
presented with a dedifferentiated component and to
determine the risk of recurrence of these tumours.
Materials and methods
The study was undertaken as part of a departmental
audit and was also covered by ethical approval
EC17.14 under Human Tissue Authority license
12055. An electronic search of the pathology archive
was undertaken for all peripherally-sited ALT, pre-
senting between January 1997 and June 2009, includ-
ing those with and without a de novo dedifferentiated
component. This provided a patient cohort with mini-
mum of a 60 months follow-up. The first search
included only those patients who had their first sur-
gery at a specialist sarcoma centre and only those
tumours with MDM2 amplification were included.
The search was then extended to include all
patients diagnosed with ALT (all with MDM2 ampli-
fication) and comprised patients who had their first
surgical treatment outside the specialist sarcoma
centre. The purpose was to determine the range of
time from primary resection of ALT to local recur-
rence and to increase the numbers to identify how
often recurrent tumours recurred more than once and
how often these transformed into dedifferentiated lip-
osarcoma (secondary DDLS).
All cases were reviewed by experienced histopa-
thologists (AMF, RT, MFA). The diagnoses of ALT
and DDLS were classified according to criteria
reported in 2013 [10]. ALT were subclassified as
‘lipoma-like’, sclerosing, inflammatory, and DDLS
with heterologous differentiation [10]. Fluorescence
in situ hybridisation (FISH) for MDM2 amplification
was performed on all samples.
Surgical excision was considered ‘marginal’ if
tumour was covered with less than 10 mm of normal
or reactive tissue and ‘wide’ if excised with 10 mm
or more of normal or reactive surrounding tissue.
Surgical excision was classified as intralesional if
tumour was exposed during the surgical procedure.
Fluorescence in situ hybridisation
FISH for MDM2 amplification was performed on all
samples. In brief, and as previously described, a full tis-
sue block section from each lipomatous neoplasm was
examined by FISH using the ZytoLight SPEC MDM2/
CEN12 Dual Colour Probe kit (ZytoVision GmbH,
Bremerhaven, Germany). This probe cocktail deco-
rates the human chromosomal region MDM2 with a
green signal and the alpha satellite centromeric
region of chromosome 12 (D12Z3 sequences) with a
red signal. The centromere of chromosome 12
(CEN12) is detected as a strong, intense red signal,
whereas integrated alpha satellite 12 sequences
(alphoid 12 signals) located at ring or marker chro-
mosome are detected as faint signals compared with
that of CEN12. FISH was performed according to the
manufacturer’s protocol [11].
Evaluation of the sampled tissue sections was car-
ried out using fluorescence microscopy on an Olym-
pus BX-51 (Olympus, Southall, Middlesex, UK). The
number of each signal for MDM2 (green) and
CEN12 (centromere 12; red) was scored by counting
a minimum of 50 nonoverlapping nuclei per case,
and the average number of MDM2 and CEN12 sig-
nals was then calculated. A ratio of greater than 2.0
was considered to represent MDM2 amplification, a
ratio of less than or equal to 2 was considered to be
nonamplified. Regardless of the MDM2: CEN12
ratio, an average of 3 or more signals for CEN12
was considered to represent copy number gain of
both CEN12 and MDM2 (referred to by others previ-
ously as aneusomy or polysomy). All FISH was
reviewed by at least two experienced individuals.
Results
Atypical lipomatous tumours: 1997–2009 (n5 90)
Ninety-six patients, 53 men and 43 women, presented
with ALT between 1997 and 2009 but six patients
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died of another disease before reaching 60 months
follow-up and these were excluded from the study.
The mean age of the remaining 90 patients at presen-
tation was 57 years (median: 61; range: 22–92). The
most common location was the thigh (n5 70); other
less common locations were: upper arm/shoulder
(n5 5), buttock (n5 3), groin (n5 4), lower leg/calf
(n5 4), axilla (n5 3) and back (n5 1). The mean
size of these tumours at diagnosis was 195 mm
(range: 35–340mm): only two cases measured less
than 50mm. Eighty-eight were classified as ‘lipoma-
like’ variant, one as sclerosing variant and one as
inflammatory variant.
All 90 patients who presented with ALT were fol-
lowed for a minimum of 60 months. The median and
mean follow-up period of 90 individuals was 96 and
112 months, respectively. Eight of the 90 (8.9%)
tumours recurred locally: seven recurred once and
one recurred twice. The earliest recurrence was at 12
months, the latest was at 156 months and four of the
eight recurrences occurred after 60 months (Table 1).
In the one patient whose tumour recurred twice, the
second recurrence presented as a DDLS (110mm).
All patients with recurrences are alive and none of
the tumours has metastasised. Seven of the eight
recurrent tumours were detected by self-examination
by the patient. The other was detected by follow-up
magnetic resonance scanning.
The majority of tumours (88/90) were resected
with a marginal/complete excision margin (Figure 1).
Two cases had documented evidence of intralesional
excisions, and both of these recurred. The mean size
of the eight recurrent tumours (first recurrent events)
was 133mm (range 75–280mm). The size of the first
recurrence in each case was smaller than the primary
tumour (one-tailed t-test, p5 0.0043). The size of the
case which recurred a second time (secondary
DDLS) was 110mm and was smaller than the pre-
senting tumour (245mm) and the first recurrence
(280mm).
Extended study
In addition to the 90 cases of ALT included in the
primary study (vide supra), an extended search of
our archive revealed an additional 175 cases giving a
total of 265 cases that presented to the RNOH
between 1997 and 2014. Of these, 155 cases pre-
sented after 2009 and, therefore, had limited follow-
up. Furthermore, 18 of this extended group presented
at RNOH with recurrent disease. One of these recur-
rent cases (thigh) presented at RNOH 40 years after
the first excision. Twenty-six (including eight in the
primary study) of the 265 (10%) cases presented with
recurrent ALT: 19 (73%) recurred once as ALT and
7 (27%) recurred more than once as ALT: 3 of the
latter (n5 7) presented as secondary DDLS on the
final recurrence. Details of these seven tumours are
shown in Table 2. The mean size of the recurrent
tumours was 143mm (range 40–250mm). Only two
cases measured less than 100mm. The majority
(89%) of these tumours were resected with a com-
plete/marginal excision margin.
Table 1. Clinical data on 8 of 90 patients presenting with recurrent ALT between 1997 and 2009
Site
Margin
status
Year of presentation and tumour size at each presentation Follow-up
period
from first
presentation
(months)
Primary
tumour
Tumour
size (mm)
First
recurrence
Tumour
size (mm)
Second
recurrence
Tumour
size (mm)
Case 1 Thigh Marginal 1997 245 2010 210 2012 110 192
Case 2 Leg Intralesional 1999 265 2013 110 168
Case 3 Axilla Marginal 2006 240 2013 110 84
Case 4 Thigh Marginal 2002 230 2008 180 132
Case 5 Thigh Marginal 1999 235 2004 75 156
Case 6 Arm Marginal 2008 100 2012 60 60
Case 7 Thigh Marginal 2008 340 2012 90 60
Case 8 Thigh Intralesional 2005 170 2006 130 96
Figure 1. Large bosselated ALT which appears to be completely
excised and covered by a thin film of loose fibrous tissue (mar-
ginal excision). Maximum dimension of tumour5 240mm.
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De novo dedifferentiated liposarcoma: 1997–2009
(n5 18)
Eighteen peripherally-sited de novo DDLS were iden-
tified during 1997–2009, representing 16% of all
ALT (those with and without a de novo dedifferenti-
ated component). This patient group comprised nine
men and nine women with a mean age of 60 (range:
30–86 years). The anatomical locations of the de
novo DDLS were similar to that of the fully mature
ALT: thigh (n5 8), upper arm/shoulder (n5 4), but-
tock (n5 2) and lower leg/calf (n5 2) and chest wall
(n5 2). &&The mean size of theses tumours at first
presentation was 161mm (range 40–360mm). Two
of 18 cases had a heterologous component, one with
an osteosarcomatous component and the other with a
rhabdomyosarcomatous component (Figure 2).
Of the 18 patients who presented with a de novo
DDLS, 11 were followed for a minimum of 60
months; the other seven patients died before this
time, but only two died of their disease. The median
and mean follow-up period was 72 months, and 75
months, respectively. Three (17%) of the de novo
DDLS recurred, two recurring locally once and a
third case recurring locally once and subsequently
developing metastatic disease at two sites. All three
tumours recurred within 60 months of presentation.
The mean size of the recurrent tumours was 220mm
(range 160–290mm).
Discussion
We studied 90 patients with ALT, presenting
between 1997 and 2009, all of whom underwent their
first resection at a single specialist sarcoma unit, and
showed that with a minimum follow-up of 60 months
the recurrence rate was 8.9%. Fifty percent of the
tumours recurred within the first 60 months, with the
remainder recurring up to 12 years later. One patient
represented 40 years following their first surgical
excision indicating that relapse can occur several
decades after the first treatment.
There have been numerous reports of the incidence
of recurrence of peripheral ALT, based on datasets
that are often not comparable [12]. In some studies,
the follow up period is short, a factor highlighted by
Kooby et al [8] who showed that in their cohort
(mean follow-up 47 months) recurrences only
Table 2. Clinical data on 7 of 26 patients who had more than one tumour recurrence
Site
Year of presentation and tumour size at each presentation
Primary
tumour
Tumour size
(mm)*
First
recurrence
Tumour size
(mm)
Second
recurrence
Tumour size
(mm)
Third
recurrence
Tumour size
(mm)
Fourth
recurrence
Tumour
size (mm)
Case 1 Thigh 1984 Unknown 1994 270 2004 230 2009 220 2013 190
Case 2 Thigh 1981 Unknown 1987 240 2007 210 2011 110
Case 3 Forearm 1995 Unknown 2004 140 2005 90
Case 4 Arm 1999 Unknown 2003 120 2010 90
Case 5 Thigh 2002 Unknown 2004 100 2006 170
Case 6 Thigh 1995 Unknown 1999 160 2005 50
Case 7 Thigh 1997 245 2010 210 2012 110
*All tumours with an unknown size did not have surgery at RNOH.
These patients had their primary surgery anytime from 1980 onwards.
Figure 2. Light photomicrographs of de novo dedifferentiated ALT showing evidence of heterologous differentiation. (a) Haematoxylin
and eosin-stained section showing osteosarcomatous differentiation with osteoid deposition [HE,3 200]. (b) Rhabdomyosarcomatous
differentiation [HE,3 100] is confirmed by (c) myogenin immunoreactivity [3200].
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occurred beyond 60 months. Whereas this is likely to
under-represent the number of recurrences, recur-
rences may be over-represented in studies that
include a significant number of patients referred
with relapsed disease to a specialist unit, whose ini-
tial surgery was not undertaken in a specialist unit.
This is supported by the observation that the publi-
cations with the highest incidence of recurrent dis-
ease are reported from large highly specialist
centres and, therefore, likely to reflect selection bias
[1,4,7]. This is further highlighted in a study by
Mavrogenis et al [12] in which the local recurrence
rate in patients diagnosed and treated at their insti-
tution at the time of first presentation was 10.6%,
which is not dissimilar to our figure of 8.9%. How-
ever, when patients referred for treatment of recur-
rent disease were included in their calculations, the
recurrence rate increased to 25% [12]. Our inci-
dence of recurrence increased to 10% when we
included patients referred with recurrent disease.
However, this figure is not a true reflection of the
recurrence rate for two reasons: firstly patients
referred with a recurrent tumour introduces a selec-
tion bias into the calculation, and secondly this
group includes 155 patients with ALT who have
had limited follow up (less than 60 months).
Distinguishing peripheral ALT from large lipomas
using microscopy alone is challenging [7,11,13]. The
presence of either ring chromosomes and/or giant
marker chromosomes detected by cytogenetics or
MDM2 amplification by FISH or PCR has been
shown by several groups to be valuable for distin-
guishing these tumours [5,7,9,11,13,14]. Zhang et al
[7] and Neuville et al [13] showed that this molecu-
lar test resulted in the diagnosis of ALT being
changed to lipoma in 21% (11/52) and 18% (6/33) of
cases respectively, but that the reverse was much
lower (2%) [7]. In the past, this molecular bio-
marker was not always used [1,2,8,12,15] and, there-
fore, is also likely to have contributed to the different
reported incidence of recurrence of ALT.
Since ALT are frequently large at presentation
(mean of 195mm, range of 35–340mm in this study),
and often have a complex, bosselated contour, they
are surgically challenging. In the UK, it is recom-
mended, that such tumours are excised at specialist
sarcoma units and this is likely to account for the low
incidence of ALT (2/96) that were found to have
demonstrable intralesional excisions. In the two cases
with obvious intralesional excision, a clinical decision
was made that this was the appropriate surgical man-
agement to preserve the adjacent neurovascular struc-
ture. However, as both tumours recurred, it suggests
that intralesional excision is a significant risk factor
for recurrence and highlights the need for detailed
examination of the gross specimen by the pathologist.
Local recurrence is associated with an increased
risk of secondary dedifferentiation which has meta-
static potential [4,12,16]: this was confirmed in our
extended study, which included ALT presenting out-
side the 1997–2009 period and patients referred from
other hospitals because of recurrent disease. These
data showed that three of seven patients with multi-
ple recurrent ALT developed a dedifferentiated com-
ponent either at or subsequent to the second
recurrence. Taken together, the findings underscore
the need for appropriate initial surgical management.
ALT are low grade neoplasms and the majority
presents as large tumours (>10 cm): by definition
they are slow-growing and therefore are likely to
have been present for many years before presentation.
In view of the evidence that dedifferentiation is time-
dependent [1], it is therefore not surprising that we
identified that 17% (18 of 108) of all ALT at presen-
tation had a dedifferentiated component. This figure
is consistent with the reports by others [1,3,4]. De
novo DDLS behave more aggressively than conven-
tional ALT: of our 18 cases, 17% recurred, behaviour
comparable to that of other high grade sarcomas of
the limb [17]. As with other intermediate and high
grade sarcomas in our centre, DDLS is frequently
treated with post-operative radiotherapy and patients
are monitored according to the ESMO/ European Sar-
coma Network Working Group, 2012 guidelines [17].
Tumours are conventionally classified as benign and
malignant, although these categories often do not
reflect the wide spectrum of behaviour of tumours.
ALT is an example of the challenge of conveying to
patients the degree of seriousness of a disease which
some doctors refer to as cancer, whereas others may
refer to it is as a tumour with a low risk of recurrence
and may even label it as benign. The robust outcome
data for patients with ALT in this study will help doc-
tors clarify for their patients what they want to know
about their disease. However, acquiring such data can
be challenging if a disease is rare, and this is com-
pounded when the tumour is slow-growing and recurs
late but highlights the needs for specialist hospitals.
There is considerable difference in opinion as to
how best follow up patients treated for excision of
peripherally sited ALT. Should such patients be seen
regularly and indefinitely on the basis that a tumour
can recur as late as 40 years, or discharged on the
basis that only 8% recur within 5 years (if treated in
a specialist unit)? The recent publication by Cassier
et al [18] further complicates the issue because in
their multicentre study including 283 ALT of the
extremities, trunk and girdle (median follow up of
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61.7 months) they found that adjuvant radiotherapy
reduces the risk of local relapse. However, they com-
ment that the use of radiotherapy for a ‘benign’
tumour should be considered with caution, because
of the potential side effects of radiotherapy (in partic-
ular, risk of second malignancy). On the evidence
accrued from our study, we consider that there is jus-
tification for the current practice used in our institu-
tion: our guidelines require a post-operative
assessment at approximately 6 weeks following sur-
gery and the patients are educated about self-
examination for detection of tumour recurrence.
There is good evidence that this is effective as seven
of the eight patients with local recurrence in our
study detected their recurrent disease on self-
examination. Provided there is good wound healing
and no other complications, the patient is given a
‘supported discharge’ note for their general practi-
tioners: this provides them with rapid and direct
access to our specialist care unit if they have con-
cerns about possible recurrent disease. However, if
an intralesional excision is performed the patient is
assessed at regular intervals by clinical examination
and magnetic resonance imaging, although we
acknowledge that the benefit of monitoring patients
using the latter is not evidence-based and requires
prospective data collection.
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